Serum Pro‐N‐Cadherin Is a Marker of Subclinical Heart Failure in the General Population

Abstract

Background We recently reported aberrant processing and localization of the precursor PNC (pro‐N‐cadherin) protein in failing heart tissues and detected elevated PNC products in the plasma of patients with heart failure. We hypothesize that PNC mislocalization and subsequent circulation is an early event in the pathogenesis of heart failure, and therefore circulating PNC is an early biomarker of heart failure. Methods and Results In collaboration with the Duke University Clinical and Translational Science Institute's MURDOCK (Measurement to Understand Reclassification of Disease of Cabarrus and Kannapolis) study, we queried enrolled individuals and sampled 2 matched cohorts: a cohort of individuals with no known heart failure at the time of serum collection and no heart failure development in the following 13 years (n=289, cohort A) and a matching cohort of enrolled individuals who had no known heart failure at the time of serum collection but subsequently developed heart failure within the following 13 years (n=307, cohort B). Serum PNC and NT‐proBNP (N‐terminal pro B‐type natriuretic peptide) concentrations in each population were quantified by ELISA. We detected no significant difference in NT‐proBNP rule‐in or rule‐out statistics between the 2 cohorts at baseline. In participants who developed heart failure, serum PNC is significantly elevated relative to those who did not report development of heart failure (P6 ng/mL have a 41% increased risk of all‐cause mortality independent of age, body mass index, sex, NT‐proBNP, blood pressure, previous heart attack, and coronary artery disease (P=0.044, n=596). Conclusions These data suggest that PNC is an early marker of heart failure and has the potential to identify patients who would benefit from early therapeutic intervention.

Keywords

• biomarkers
• BNP
• cardiovascular disease
• heart failure
• NT‐proBNP
• pro‐N‐cadherin